Gastrointestinal Stents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type (Biliary Stent, Colonic Stent, Duodenal Stent, Esophageal Stent, Pancreatic Stent), By Application (Biliary Disease, Colorectal Cancer, Stomach Cancer, Inflammatory Bowel Disease, Others), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 557.19 Million
CAGR (2026-2031)	5.58%
Fastest Growing Segment	Stomach Cancer
Largest Market	North America
Market Size (2031)	USD 771.78 Million

Market Overview

The Global Gastrointestinal Stents Market will grow from USD 557.19 Million in 2025 to USD 771.78 Million by 2031 at a 5.58% CAGR. Gastrointestinal stents are expandable tubular devices, typically composed of metal or plastic, designed to restore luminal patency in obstructed regions of the alimentary tract such as the esophagus, biliary tree, and colon. The market is primarily propelled by the rising global incidence of gastrointestinal malignancies and the expanding geriatric population, which is naturally more susceptible to digestive blockages. Furthermore, the clinical shift toward minimally invasive endoscopic interventions, which offer reduced recovery times compared to traditional surgery, serves as a fundamental driver for product demand.

However, the occurrence of post-procedural complications, including stent migration, tumor ingrowth, and occlusion, remains a significant challenge that could impede broader market expansion. The urgency for effective obstruction management is highlighted by the substantial burden of related diseases. According to the American Cancer Society, in 2025, an estimated 154,270 new cases of colorectal cancer were projected to be diagnosed in the United States. This high volume of diagnoses underscores the critical necessity for reliable stenting solutions to manage obstructions and improve patient quality of life.

Key Market Drivers

The primary driver propelling the Global Gastrointestinal Stents Market is the rising incidence of gastrointestinal cancers, particularly esophageal and biliary malignancies, which necessitate palliative stenting to restore luminal patency. As the global burden of digestive cancers intensifies, the clinical need for effective obstruction management tools has surged to address dysphagia and blockage symptoms in patients with inoperable tumors. According to the American Cancer Society, January 2025, in the 'Cancer Facts & Figures 2025' report, approximately 22,070 new cases of esophageal cancer were projected to be diagnosed in the United States alone. This expanding patient pool directly amplifies the demand for durable stenting solutions, positioning them as a critical component in oncology supportive care.

Concurrently, the growing preference for minimally invasive endoscopic procedures is significantly accelerating market adoption, as healthcare providers shift away from traditional open surgeries. This transition is supported by the development of advanced stent designs that facilitate precise placement and reduce complications, thereby encouraging higher procedural volumes. The financial performance of major industry players reflects this robust demand for endoscopic interventions. According to Boston Scientific, February 2025, in the 'Fourth Quarter and Full Year 2024 Financial Results', the company's MedSurg segment, which encompasses its endoscopy portfolio, reported a 12.4% increase in net sales on a reported basis. Furthermore, broader market health is evidenced by strong profitability in the sector; according to Olympus, in 2025, the company recorded an adjusted operating profit of ¥188.5 billion in its fiscal year results, underscoring the substantial economic value driven by these medical technologies.

Download Free Sample Report

Key Market Challenges

The post-procedural complications associated with gastrointestinal stents, specifically stent migration, tumor ingrowth, and occlusion, represent a critical challenge impeding market growth. These adverse events often necessitate repeat interventions, which increases the physical burden on patients and imposes additional financial costs on healthcare systems. When stents fail to maintain luminal patency due to tissue overgrowth or displacement, the perceived reliability of these devices diminishes. Consequently, healthcare providers may exercise caution in recommending stenting for obstruction management, potentially limiting the volume of procedures performed and slowing the overall uptake of these devices in clinical practice.

The impact of these complications is magnified by the high prevalence of conditions requiring biliary drainage, where device failure can be particularly detrimental. According to the American Society of Clinical Oncology, in 2024, an estimated 66,440 adults in the United States were diagnosed with pancreatic cancer. As pancreatic malignancies frequently cause biliary obstructions requiring stenting, the persistent risk of occlusion or migration in such a large patient population presents a substantial barrier to market confidence. The frequency of these adverse events continues to restrain the aggressive expansion of the gastrointestinal stents market.

Key Market Trends

The rise of Lumen-Apposing Metal Stents (LAMS) is transforming the management of pancreatic fluid collections and biliary obstructions by enabling therapeutic drainage without the need for traditional surgery. These specialized dumbbell-shaped devices create a stable, temporary conduit between the gastrointestinal tract and adjacent cavities, significantly reducing procedural complexity for conditions such as walled-off necrosis. This technical shift toward interventional solutions is directly evidenced by the commercial performance of leading device platforms. According to Boston Scientific, February 2025, in the 'Fourth Quarter and Full Year 2024 Financial Results' report, the company’s endoluminal surgery franchise delivered double-digit growth, a performance explicitly attributed to the sustained adoption of the AXIOS stent platform and its expanded regulatory approval for gallbladder drainage in Japan.

Simultaneously, the adoption of biodegradable and bioresorbable stents is gaining traction as a solution to eliminate secondary removal procedures and reduce long-term device-related complications. These advanced stents are engineered to maintain luminal patency for a defined period before gradually dissolving, thereby mitigating risks such as stent migration and tissue ingrowth that are frequently associated with permanent metal or plastic alternatives. The clinical validation of these devices is accelerating their integration into standard practice. According to Frontline Gastroenterology, 2025, in the article 'Use of biodegradable stents in ERCP: lessons from a single high-volume centre', a retrospective study of 132 patients demonstrated the effective application of these dissolving stents for complex biliary and pancreatic indications, underscoring their utility in lowering the burden of repeat interventions.

Segmental Insights

The Stomach Cancer segment currently represents the fastest-growing category within the Global Gastrointestinal Stents Market, driven primarily by the rising prevalence of malignant gastric outlet obstructions. As gastric malignancies advance, they frequently block the digestive pathway, creating a critical demand for palliative interventions to restore oral intake. Healthcare providers are increasingly adopting endoscopic placement of self-expandable metallic stents (SEMS) over traditional surgical bypass procedures, citing significantly reduced patient recovery times and lower morbidity. This clinical shift toward minimally invasive palliative care, supported by an aging global population, underpins the segment’s accelerated expansion.

Regional Insights

North America maintains a dominant position in the global gastrointestinal stents market, driven primarily by the rising prevalence of digestive tract malignancies and biliary disorders. This regional leadership is supported by established healthcare infrastructure and comprehensive reimbursement policies managed by organizations like the Centers for Medicare & Medicaid Services. Furthermore, the market benefits from the concentrated presence of major medical device manufacturers and a clear regulatory pathway established by the U.S. Food and Drug Administration. These combined factors foster a favorable environment for the widespread adoption of interventional endoscopic procedures throughout the region.

Recent Developments

• In February 2025, Micro-Tech Endoscopy completed the acquisition of a 51% stake in Creo Medical S.L.U. (CME), a subsidiary of Creo Medical Group plc. The transaction, finalized in Madrid, was part of Micro-Tech's strategy to strengthen its international presence and optimize its global distribution network for endoscopic diagnostic and therapeutic devices. CME serves as a key distributor in the European market, marketing products for gastroenterology, urology, and pulmonology. This acquisition allows Micro-Tech to integrate its high-quality stent and endoscopy products more effectively into CME’s existing portfolio, fostering growth and collaboration between the entities.
• In December 2024, Duomed UK was appointed as the exclusive distribution partner for M.I. Tech’s HANAROSTENT portfolio in the United Kingdom. This strategic collaboration grants Duomed UK the rights to distribute M.I. Tech’s range of non-vascular self-expanding metal stents, which are widely used for clearing obstructions in the gastrointestinal system, including the biliary tree, esophagus, colon, and duodenum. M.I. Tech, a leading manufacturer in the sector, aims to leverage Duomed’s established network to enhance service delivery and meet the specific needs of healthcare professionals and patients in the region.
• In July 2024, CGBIO received approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its ARISTENT biliary stent, marking a significant step in the company's global expansion into the gastrointestinal stent market. The newly approved device is designed to treat obstructions in the bile duct, a condition that can lead to severe complications such as jaundice and liver damage. The company highlighted that the stent's delivery system focuses on user convenience, allowing practitioners to deploy the device with minimal force. Following this approval, CGBIO plans to broaden its portfolio by releasing additional stents for the esophagus, duodenum, and colon.
• In March 2024, Olympus Corporation announced the rescission of its definitive agreement to acquire Taewoong Medical Co., Ltd., a Korea-based manufacturer of gastrointestinal metallic stents. The decision was made following the discovery of data integrity issues related to Taewoong Medical’s products after the transaction’s closing in January 2024. Olympus determined that these findings were inconsistent with the representations and warranties provided prior to the closing. Consequently, the former shareholders of Taewoong Medical refunded the purchase amount, and Olympus agreed to return all shares of the company, effectively unwinding the deal to acquire the stent manufacturer.

Key Market Players

• Boston Scientific Corporation
• Cook Group Inc.
• Becton Dickinson & Co Ltd
• CONMED Corporation
• Cantel Medical LLC
• ELLA-CS, s.r.o.
• Hobbs Medical Inc.
• Merit Medical Systems, Inc.
• Olympus Corp.
• Diagmed Healthcare Ltd.

By Product Type	By Application	By Region
Biliary Stent Colonic Stent Duodenal Stent Esophageal Stent Pancreatic Stent	Biliary Disease Colorectal Cancer Stomach Cancer Inflammatory Bowel Disease Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Gastrointestinal Stents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Gastrointestinal Stents Market, By Product Type:

• Biliary Stent
• Colonic Stent
• Duodenal Stent
• Esophageal Stent
• Pancreatic Stent

• Gastrointestinal Stents Market, By Application:

• Biliary Disease
• Colorectal Cancer
• Stomach Cancer
• Inflammatory Bowel Disease
• Others

• Gastrointestinal Stents Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE